ATAI Life Sciences/$ATAI
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About ATAI Life Sciences
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.
Ticker
$ATAI
Sector
Primary listing
Employees
54
Headquarters
Website
ATAI Metrics
BasicAdvanced
$1.5B
-
-$0.82
1.62
-
Price and volume
Market cap
$1.5B
Beta
1.62
52-week high
$6.75
52-week low
$1.15
Average daily volume
3.8M
Financial strength
Current ratio
7.898
Quick ratio
6.927
Long term debt to equity
3.081
Total debt to equity
3.843
Interest coverage (TTM)
-48.36%
Profitability
EBITDA (TTM)
-99.424
Gross margin (TTM)
83.86%
Net profit margin (TTM)
-5,109.08%
Operating margin (TTM)
-3,324.22%
Effective tax rate (TTM)
0.27%
Revenue per employee (TTM)
$60,000
Management effectiveness
Return on assets (TTM)
-28.67%
Return on equity (TTM)
-100.78%
Valuation
Price to revenue (TTM)
243.447
Price to book
6.11
Price to tangible book (TTM)
6.24
Price to free cash flow (TTM)
-8.812
Free cash flow yield (TTM)
-11.35%
Free cash flow per share (TTM)
-0.444
Growth
Revenue change (TTM)
811.78%
Earnings per share change (TTM)
3.25%
3-year revenue growth (CAGR)
92.21%
3-year earnings per share growth (CAGR)
-13.73%
What the Analysts think about ATAI
Analyst ratings (Buy, Hold, Sell) for ATAI Life Sciences stock.
ATAI Financial Performance
Revenues and expenses
ATAI Earnings Performance
Company profitability
ATAI News
AllArticlesVideos
AtaiBeckley receives new US patent for oral R-MDMA formulation EMP-01
Proactive Investors·1 week ago
AtaiBeckley advances clinical pipeline, strengthens balance sheet in Q3
Proactive Investors·1 month ago
AtaiBeckley reports positive data supporting repeated dosing of BPL-003 in treatment-resistant depression patients
Proactive Investors·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ATAI Life Sciences stock?
ATAI Life Sciences (ATAI) has a market cap of $1.5B as of December 19, 2025.
What is the P/E ratio for ATAI Life Sciences stock?
The price to earnings (P/E) ratio for ATAI Life Sciences (ATAI) stock is 0 as of December 19, 2025.
Does ATAI Life Sciences stock pay dividends?
No, ATAI Life Sciences (ATAI) stock does not pay dividends to its shareholders as of December 19, 2025.
When is the next ATAI Life Sciences dividend payment date?
ATAI Life Sciences (ATAI) stock does not pay dividends to its shareholders.
What is the beta indicator for ATAI Life Sciences?
ATAI Life Sciences (ATAI) has a beta rating of 1.62. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.